selected publications
-
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 37 -
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
Journal of gynecologic oncology.
2020
Academic Article
GET IT
Times cited: 22 -
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Cancer.
2019
Academic Article
GET IT
Times cited: 47 -
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gynecologic oncology.
2019
Academic Article
GET IT
Times cited: 9 -
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
The Lancet. Oncology.
2019
Academic Article
GET IT
Times cited: 198 -
The Experience of Being Aware of Disease Status in Women with Recurrent Ovarian Cancer: A Phenomenological Study.
Journal of palliative medicine.
2018
Academic Article
GET IT
Times cited: 11 -
It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
Gynecologic oncology.
2018
Information Resource
GET IT
Times cited: 29 -
Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
Gynecologic oncology.
2018
Academic Article
GET IT
Times cited: 21 -
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.
Molecular therapy. Methods & clinical development.
2018
Academic Article
GET IT
Times cited: 23 - Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2017 Information Resource GET IT
-
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?.
Gynecologic oncology.
2017
Academic Article
GET IT
Times cited: 61 -
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Gynecologic oncology.
2016
Academic Article
GET IT
Times cited: 14 -
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Gynecologic oncology.
2016
Academic Article
GET IT
Times cited: 3 -
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.
Cancers.
2016
Academic Article
GET IT
Times cited: 36 -
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Gynecologic oncology.
2016
Academic Article
GET IT
Times cited: 102 -
Is It Time to Centralize Ovarian Cancer Care in the United States?.
Annals of surgical oncology.
2015
Review
GET IT
Times cited: 47 -
Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2015
Academic Article
GET IT
Times cited: 13 -
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Journal of translational medicine.
2015
Academic Article
GET IT
Times cited: 227 -
Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer.
Gynecologic oncology.
2014
Academic Article
GET IT
Times cited: 11 -
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
Gynecologic oncology.
2014
Academic Article
GET IT
Times cited: 29 -
Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.
Gynecologic oncology.
2012
Academic Article
GET IT
Times cited: 42 -
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2012
Academic Article
GET IT
Times cited: 2 -
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Gynecologic oncology.
2011
Academic Article
GET IT
Times cited: 54 -
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
Gynecologic oncology.
2009
Academic Article
GET IT
Times cited: 44 -
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
Gynecologic oncology.
2009
Academic Article
GET IT
Times cited: 83 -
Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation.
Irish journal of medical science.
2008
Academic Article
GET IT
Times cited: 9